BioCentury | Aug 18, 2010
Company News

Amarin names Stewart CEO

...Stewart as president, CEO and a director. He is the former president and CEO of CollaGenex Pharmaceuticals Inc....
BioCentury | Jun 1, 2009
Company News

Orthovita management update

...Business: Dermatology, Musculoskeletal Hired: Nancy Broadbent as SVP and CFO, formerly SVP and CFO at CollaGenex Pharmaceuticals Inc....
BioCentury | Nov 17, 2008
Company News

Nitric BioTherapeutics management update

...Business: Infectious, Dermatology Hired: David Pfeiffer as COO, formerly SVP of sales and marketing at CollaGenex Pharmaceuticals Inc. WIR...
BioCentury | Oct 6, 2008
Finance

4Q Financial Markets Preview: Arrested development

...Pharmion Corp. , Millennium Pharmaceuticals Inc. (now part of Takeda Pharmaceutical Co. Ltd. ), Collagenex Pharmaceuticals Inc....
...Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. CollaGenex Pharmaceuticals Inc....
BioCentury | Aug 4, 2008
Finance

Ebb & Flow

...front and up to €24 million ($37.8 million) in milestones. MediGene has European rights from CollaGenex...
BioCentury | Aug 4, 2008
Company News

Galderma, Medigene deal

...has worldwide rights to the once-daily sub-antimicrobial formulation of doxycycline. MediGene had European rights from CollaGenex Pharmaceuticals Inc....
BioCentury | Jul 30, 2008
Company News

EC approves MediGene's Oracea

...doxycycline is marketed in the U.S. by CollaGenex , from whom MediGene has European rights. CollaGenex...
BioCentury | Jul 7, 2008
Finance

Casting a wider net

...of selling and had several takeouts or proposed M&A transactions, including Millennium Pharmaceuticals Inc. , Collagenex Pharmaceuticals Inc....
BioCentury | Apr 28, 2008
Clinical News

Oracea regulatory update

...resistance to the agent. Galderma obtained the delayed-release formulation of doxycycline through its acquisition of CollaGenex Pharmaceuticals Inc....
BioCentury | Apr 14, 2008
Company News

CollaGenex, Galderma deal

...Galderma completed its previously announced cash tender offer for shares of CollaGenex at $16.60 per share...
...March 3). Galderma plans to acquire the remaining shares at $16.60 via a merger agreement. CollaGenex Pharmaceuticals Inc....
Items per page:
1 - 10 of 230
BioCentury | Aug 18, 2010
Company News

Amarin names Stewart CEO

...Stewart as president, CEO and a director. He is the former president and CEO of CollaGenex Pharmaceuticals Inc....
BioCentury | Jun 1, 2009
Company News

Orthovita management update

...Business: Dermatology, Musculoskeletal Hired: Nancy Broadbent as SVP and CFO, formerly SVP and CFO at CollaGenex Pharmaceuticals Inc....
BioCentury | Nov 17, 2008
Company News

Nitric BioTherapeutics management update

...Business: Infectious, Dermatology Hired: David Pfeiffer as COO, formerly SVP of sales and marketing at CollaGenex Pharmaceuticals Inc. WIR...
BioCentury | Oct 6, 2008
Finance

4Q Financial Markets Preview: Arrested development

...Pharmion Corp. , Millennium Pharmaceuticals Inc. (now part of Takeda Pharmaceutical Co. Ltd. ), Collagenex Pharmaceuticals Inc....
...Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. CollaGenex Pharmaceuticals Inc....
BioCentury | Aug 4, 2008
Finance

Ebb & Flow

...front and up to €24 million ($37.8 million) in milestones. MediGene has European rights from CollaGenex...
BioCentury | Aug 4, 2008
Company News

Galderma, Medigene deal

...has worldwide rights to the once-daily sub-antimicrobial formulation of doxycycline. MediGene had European rights from CollaGenex Pharmaceuticals Inc....
BioCentury | Jul 30, 2008
Company News

EC approves MediGene's Oracea

...doxycycline is marketed in the U.S. by CollaGenex , from whom MediGene has European rights. CollaGenex...
BioCentury | Jul 7, 2008
Finance

Casting a wider net

...of selling and had several takeouts or proposed M&A transactions, including Millennium Pharmaceuticals Inc. , Collagenex Pharmaceuticals Inc....
BioCentury | Apr 28, 2008
Clinical News

Oracea regulatory update

...resistance to the agent. Galderma obtained the delayed-release formulation of doxycycline through its acquisition of CollaGenex Pharmaceuticals Inc....
BioCentury | Apr 14, 2008
Company News

CollaGenex, Galderma deal

...Galderma completed its previously announced cash tender offer for shares of CollaGenex at $16.60 per share...
...March 3). Galderma plans to acquire the remaining shares at $16.60 via a merger agreement. CollaGenex Pharmaceuticals Inc....
Items per page:
1 - 10 of 230